PI3K-AKT/mTOR Signaling in Psychiatric Disorders: A Valuable Target to Stimulate or Suppress?
International Journal of Neuropsychopharmacology · 01.02.2024 · 27 (2)
DOI: 10.1093/ijnp/pyae010 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Neuropsychopharmacology, online erschienen am 14.02.2024. Verfasst von Yan Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, Jiangsu, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Mental Disorders. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Economic development and increased stress have considerably increased the prevalence of psychiatric disorders in recent years, which rank as some of the most prevalent diseases globally. Several factors, including chronic social stress, genetic inheritance, and autogenous diseases, lead to the development and progression of psychiatric disorders. Clinical treatments for psychiatric disorders include psychotherapy, chemotherapy, and electric shock therapy. Although various achievements have been made researching psychiatric disorders, the pathogenesis of these diseases has not been fully understood yet, and serious adverse effects and resistance to antipsychotics are major obstacles to treating patients with psychiatric disorders. Recent studies have shown that the mammalian target of rapamycin (mTOR) is a central signaling hub that functions in nerve growth, synapse formation, and plasticity. The PI3K-AKT/mTOR pathway is a critical target for mediating the rapid antidepressant effects of these pharmacological agents in clinical and preclinical research. Abnormal PI3K-AKT/mTOR signaling is closely associated with the pathogenesis of several neurodevelopmental disorders. In this review, we focused on the role of mTOR signaling and the related aberrant neurogenesis in psychiatric disorders. Elucidating the neurobiology of the PI3K-AKT/mTOR signaling pathway in psychiatric disorders and its actions in response to antidepressants will help us better understand brain development and quickly identify new therapeutic targets for the treatment of these mental illnesses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, Jiangsu, China.
- Department of Pharmacology, Pharmacy College, Nantong University, Nantong, Jiangsu, China.
Zitieren
APA
Chen, Y., Guan, W., Wang, M. L., & Lin, X. Y. (2024). PI3K-AKT/mTOR Signaling in Psychiatric Disorders: A Valuable Target to Stimulate or Suppress?. International Journal of Neuropsychopharmacology, 27(2). https://doi.org/10.1093/ijnp/pyae010
Vancouver
Chen Y, Guan W, Wang ML, Lin XY. PI3K-AKT/mTOR Signaling in Psychiatric Disorders: A Valuable Target to Stimulate or Suppress?. International Journal of Neuropsychopharmacology. 2024;27(2). doi:10.1093/ijnp/pyae010
BibTeX
@article{Chen2024,
author = {Chen, Yan and Guan, Wei and Wang, Mei-Lan and Lin, Xiao-Yun},
title = {PI3K-AKT/mTOR Signaling in Psychiatric Disorders: A Valuable Target to Stimulate or Suppress?},
journal = {International Journal of Neuropsychopharmacology},
year = {2024},
volume = {27},
number = {2},
doi = {10.1093/ijnp/pyae010}
}
EUVIMED